<unk>  is a prophylactic antianginal agent used primarily in Australia and New Zealand.<unk>  is thought to act by inhibiting mitochondrial carnitine palmitoyltransferase-1 this shifts myocardial metabolism from fatty acid to glucose utilisation which results in increased ATP production for the same O2 consumption and consequently increases myocardial efficiency. Its clinical use has been limited by its narrow therapeutic index and high inter- and intra-individual pharmacokinetic variability. It was outlawed in many countries due to its adverse effects on poor metabolisers (PM). The product has been reintroduced for patients who have contraindications, or have not responded to, other treatments for angina.
Perhexiline
Fendiline
Selegiline 
Rasagiline
Rivastigmine
Rivastigmine 
Bedaquiline fumarate
Benperidol